manufacturing agreement

Stratec is producing the microfluidic chips for Vortex' VTX-1 system, which enables the enrichment and isolation of circulating tumor cells.

Aldevron will manufacture IDT's patented S. pyogenes HiFi Cas9 mutant for research, clinical, and commercial uses.

The companies will integrate Cambridge's TrueMethyl technology for oxidative bisulfite sequencing with NuGen's sequencing library preparation kits.

The arrayed lentiviral CRISPR/Cas9 guide RNA libraries provide the tools to knock out every known human or mouse protein-coding gene.

NEW YORK (GenomeWeb) – Microsaic Systems and Plexus today announced an agreement for the commercial manufacturing of Microsaic's 4000MiD miniature mass spectrometry system.

NEW YORK (GenomeWeb News) – Invetech will support the development and manufacture of Biocartis' multiplex platform for biomarker analysis under an agreement announced today.

NEW YORK (GenomeWeb News) – New England Biolabs today announced a manufacturing and supply agreement with molecular diagnostics firm Lumora.

NEW YORK (GenomeWeb News) – Trinean announced that it has entered into a manufacturing and supply agreement with Qiagen for the production of QIAxpert, a microvolume spectrometer for DNA and RNA quantitation and analysis.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Rubicon Genomics today said that Velesco Pharmaceutical Services will manufacture its Transplex kits that it will supply for use with Agendia's breast cancer diagnostics.

Quanterix aims to develop and manufacture an automated instrument for its SiMoA technology, which will use the "smart consumables" to support a menu of diagnostic tests.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.